These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 26063881)

  • 1. Early Surrogate Markers of Treatment Activity: Where Are We Now?
    Klintman M; Dowsett M
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):24-8. PubMed ID: 26063881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
    Yeo B; Dowsett M
    Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
    Dowsett M; Smith I; Robertson J; Robison L; Pinhel I; Johnson L; Salter J; Dunbier A; Anderson H; Ghazoui Z; Skene T; Evans A; A'Hern R; Iskender A; Wilcox M; Bliss J
    J Natl Cancer Inst Monogr; 2011; 2011(43):120-3. PubMed ID: 22043057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?
    Generali D; Ardine M; Strina C; Milani M; Cappelletti MR; Zanotti L; Forti M; Bedussi F; Martinotti M; Amoroso V; Sigala S; Simoncini E; Berruti A; Bottini A
    J Natl Cancer Inst Monogr; 2015 May; 2015(51):32-5. PubMed ID: 26063883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
    Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
    J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
    Dowsett M; Nielsen TO; A'Hern R; Bartlett J; Coombes RC; Cuzick J; Ellis M; Henry NL; Hugh JC; Lively T; McShane L; Paik S; Penault-Llorca F; Prudkin L; Regan M; Salter J; Sotiriou C; Smith IE; Viale G; Zujewski JA; Hayes DF;
    J Natl Cancer Inst; 2011 Nov; 103(22):1656-64. PubMed ID: 21960707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
    Dowsett M; Smith IE; Ebbs SR; Dixon JM; Skene A; A'Hern R; Salter J; Detre S; Hills M; Walsh G;
    J Natl Cancer Inst; 2007 Jan; 99(2):167-70. PubMed ID: 17228000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
    Tao Y; Klause A; Vickers A; Bae K; Ellis M
    J Steroid Biochem Mol Biol; 2005 May; 95(1-5):91-5. PubMed ID: 15994076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
    Takei H; Kurosumi M; Yoshida T; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Oba H; Inoue K; Nagai S; Tabei T
    Breast Cancer; 2011 Apr; 18(2):85-91. PubMed ID: 21104350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
    Zhang A; Wang X; Fan C; Mao X
    Front Endocrinol (Lausanne); 2021; 12():687244. PubMed ID: 34803903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant endocrine therapy and window of opportunity trials: new standards in the treatment of breast cancer?
    Levasseur N; Clemons M; Hilton J; Addison C; Robertson S; Ibrahim M; Arnaout A
    Minerva Chir; 2015 Jun; 70(3):181-93. PubMed ID: 25737461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
    Iwata H
    Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial.
    Ellis MJ; Miller WR; Tao Y; Evans DB; Chaudri Ross HA; Miki Y; Suzuki T; Sasano H
    Breast Cancer Res Treat; 2009 Jul; 116(2):371-8. PubMed ID: 18941892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant sequencing of tamoxifen and anastrozole is superior to tamoxifen alone in postmenopausal women with low proliferating breast cancer.
    Bago-Horvath Z; Rudas M; Dubsky P; Jakesz R; Singer CF; Kemmerling R; Greil R; Jelen A; Böhm G; Jasarevic Z; Haid A; Gruber C; Pöstlberger S; Filipits M; Gnant M;
    Clin Cancer Res; 2011 Dec; 17(24):7828-34. PubMed ID: 21998336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant use of endocrine therapy in breast cancer.
    Macaskill EJ; Dixon JM
    Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer.
    Torrisi R; Bagnardi V; Rotmensz N; Scarano E; Iorfida M; Veronesi P; Luini A; Viale G; Santoro A; Colleoni M; Goldhirsch A
    Breast Cancer Res Treat; 2011 Apr; 126(2):431-41. PubMed ID: 21221766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of pretherapeutic Ki67 as a predictive parameter for response to neoadjuvant chemotherapy in breast cancer: is it equally useful across tumor subtypes?
    Sueta A; Yamamoto Y; Hayashi M; Yamamoto S; Inao T; Ibusuki M; Murakami K; Iwase H
    Surgery; 2014 May; 155(5):927-35. PubMed ID: 24582496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic model based on combining estrogen receptor expression and Ki-67 value after neoadjuvant chemotherapy predicts clinical outcome in locally advanced breast cancer: extension and analysis of a previously reported cohort of patients.
    Miglietta L; Morabito F; Provinciali N; Canobbio L; Meszaros P; Naso C; Murialdo R; Boitano M; Salvi S; Ferrarini M
    Eur J Surg Oncol; 2013 Oct; 39(10):1046-52. PubMed ID: 23890870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.